Yuji Piao1, Soon Young Park1, Verlene Henry1, Bryan D Smith1, Ningyi Tiao1, Daniel L Flynn1, John F de Groot2. 1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (Y.P., S.Y.P., N.T., J.F.d.G.); Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (V.H.); Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts (B.D.S., D.L.F.). 2. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (Y.P., S.Y.P., N.T., J.F.d.G.); Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (V.H.); Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts (B.D.S., D.L.F.) jdegroot@mdanderson.org.
Abstract
BACKGROUND: Glioblastoma highly expresses the proto-oncogene MET in the setting of resistance to bevacizumab. MET engagement by hepatocyte growth factor (HGF) results in receptor dimerization and autophosphorylation mediating tumor growth, invasion, and metastasis. Evasive revascularization and the recruitment of TIE2-expressing macrophages (TEMs) are also triggered by anti-VEGF therapy. METHODS: We investigated the activity of altiratinib (a novel balanced inhibitor of MET/TIE2/VEGFR2) against human glioblastoma stem cell lines in vitro and in vivo using xenograft mouse models. The biological activity of altiratinib was assessed in vitro by testing the expression of HGF-stimulated MET phosphorylation as well as cell viability after altiratinib treatment. Tumor volume, stem cell and mesenchymal marker levels, microvessel density, and TIE2-expressing monocyte infiltration were evaluated in vivo following treatment with a control, bevacizumab alone, bevacizumab combined with altiratinib, or altiratinib alone. RESULTS: In vitro, HGF-stimulated MET phosphorylation was completely suppressed by altiratinib in GSC17 and GSC267, and altiratinib markedly inhibited cell viability in several glioblastoma stem cell lines. More importantly, in multiple xenograft mouse models, altiratinib combined with bevacizumab dramatically reduced tumor volume, invasiveness, mesenchymal marker expression, microvessel density, and TIE2-expressing monocyte infiltration compared with bevacizumab alone. Furthermore, in the GSC17 xenograft model, altiratinib combined with bevacizumab significantly prolonged survival compared with bevacizumab alone. CONCLUSIONS: Together, these data suggest that altiratinib may suppress tumor growth, invasiveness, angiogenesis, and myeloid cell infiltration in glioblastoma. Thus, altiratinib administered alone or in combination with bevacizumab may overcome resistance to bevacizumab and prolong survival in patients with glioblastoma.
BACKGROUND:Glioblastoma highly expresses the proto-oncogene MET in the setting of resistance to bevacizumab. MET engagement by hepatocyte growth factor (HGF) results in receptor dimerization and autophosphorylation mediating tumor growth, invasion, and metastasis. Evasive revascularization and the recruitment of TIE2-expressing macrophages (TEMs) are also triggered by anti-VEGF therapy. METHODS: We investigated the activity of altiratinib (a novel balanced inhibitor of MET/TIE2/VEGFR2) against humanglioblastoma stem cell lines in vitro and in vivo using xenograft mouse models. The biological activity of altiratinib was assessed in vitro by testing the expression of HGF-stimulated MET phosphorylation as well as cell viability after altiratinib treatment. Tumor volume, stem cell and mesenchymal marker levels, microvessel density, and TIE2-expressing monocyte infiltration were evaluated in vivo following treatment with a control, bevacizumab alone, bevacizumab combined with altiratinib, or altiratinib alone. RESULTS: In vitro, HGF-stimulated MET phosphorylation was completely suppressed by altiratinib in GSC17 and GSC267, and altiratinib markedly inhibited cell viability in several glioblastoma stem cell lines. More importantly, in multiple xenograft mouse models, altiratinib combined with bevacizumab dramatically reduced tumor volume, invasiveness, mesenchymal marker expression, microvessel density, and TIE2-expressing monocyte infiltration compared with bevacizumab alone. Furthermore, in the GSC17 xenograft model, altiratinib combined with bevacizumab significantly prolonged survival compared with bevacizumab alone. CONCLUSIONS: Together, these data suggest that altiratinib may suppress tumor growth, invasiveness, angiogenesis, and myeloid cell infiltration in glioblastoma. Thus, altiratinib administered alone or in combination with bevacizumab may overcome resistance to bevacizumab and prolong survival in patients with glioblastoma.
Authors: L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar Journal: Nat Genet Date: 1997-05 Impact factor: 38.330
Authors: Kyeung Min Joo; Juyoun Jin; Eunhee Kim; Kang Ho Kim; Yonghyun Kim; Bong Gu Kang; Youn-Jung Kang; Justin D Lathia; Kwang Ho Cheong; Paul H Song; Hyunggee Kim; Ho Jun Seol; Doo-Sik Kong; Jung-Il Lee; Jeremy N Rich; Jeongwu Lee; Do-Hyun Nam Journal: Cancer Res Date: 2012-05-22 Impact factor: 12.701
Authors: O F Olmez; E Cubukcu; T Evrensel; M Kurt; N Avci; S Tolunay; A Bekar; A Deligonul; M Hartavi; N Alkis; O Manavoglu Journal: Clin Transl Oncol Date: 2013-06-06 Impact factor: 3.405
Authors: Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape Journal: Cancer Cell Date: 2006-03 Impact factor: 31.743
Authors: Selma Pennacchietti; Paolo Michieli; Maria Galluzzo; Massimiliano Mazzone; Silvia Giordano; Paolo M Comoglio Journal: Cancer Cell Date: 2003-04 Impact factor: 31.743
Authors: Barbara Sennino; Toshina Ishiguro-Oonuma; Ying Wei; Ryan M Naylor; Casey W Williamson; Vikash Bhagwandin; Sebastien P Tabruyn; Weon-Kyoo You; Harold A Chapman; James G Christensen; Dana T Aftab; Donald M McDonald Journal: Cancer Discov Date: 2012-02-24 Impact factor: 39.397
Authors: Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis Journal: Mol Cancer Ther Date: 2017-08-24 Impact factor: 6.261
Authors: Luis Rivera Sanchez; Lucia Borriello; David Entenberg; John S Condeelis; Maja H Oktay; George S Karagiannis Journal: J Leukoc Biol Date: 2019-02-05 Impact factor: 4.962
Authors: May Elbanna; Ashley R Orillion; Nur P Damayanti; Remi Adelaiye-Ogala; Li Shen; Kiersten Marie Miles; Sreenivasulu Chintala; Eric Ciamporcero; Swathi Ramakrishnan; Sheng-Yu Ku; Karen Rex; Sean Caenepeel; Angela Coxon; Roberto Pili Journal: Mol Cancer Ther Date: 2019-10-03 Impact factor: 6.261
Authors: Y Otani; T Ichikawa; K Kurozumi; S Inoue; J Ishida; T Oka; T Shimizu; Y Tomita; Y Hattori; A Uneda; Y Matsumoto; H Michiue; I Date Journal: Oncogene Date: 2017-10-23 Impact factor: 9.867